STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More
Decision brief
Answer first · skim in under a minute
STAT+ Pharmalittle reports on Eli Lilly's ultimatum to 340B hospitals regarding claims data submission and the latest developments in Ebola vaccine funding. This news roundup highlights critical shifts in pharmaceutical access and global health initiatives.
Eli Lilly gave holdout 340B hospitals five business days to send claims data or lose discounts, while U.S. agencies raced to fund Ebola Bundibugyo vaccines amid a growing African outbreak.
Contents10 sections
Key Takeaways
- Lilly said about 70% of covered entities complied with its Feb. 1, 2026, claims-data policy; roughly 1,000 had not.
- An initial set of holdouts faced a June 8, 2026, wholesaler cutoff unless data arrived within five business days.
- CDC MMWR counted 378 confirmed Bundibugyo cases and 63 deaths as of June 2, 2026, with no approved vaccine for that species.
- BARDA sought Ervebo-platform Bundibugyo vaccine candidates as part of the HHS outbreak response.
What is Eli Lilly requiring under its 340B claims-data policy?
Lilly expanded claims-data collection on Feb. 1, 2026, to cover in-house pharmacy dispenses as well as contract pharmacy claims.
The company argues the data are needed to spot duplicate discounts, support audits, and meet Inflation Reduction Act obligations.
In a June 1, 2026, notice summarized across industry reporting, Lilly said about 2,300 distinct entities had complied and that roughly 1,000 still had not.
How fast can hospitals lose 340B pricing?
Lilly notified an initial set of holdouts—described as largely large health systems—that wholesalers would pull 340B eligibility on June 8 if data were not submitted.
Covered entities received five business days from the notice date to comply before pricing eligibility was withdrawn.
Lilly said it planned the same course for additional noncompliant entities in the weeks ahead.
What do federal 340B rules still require of manufacturers?
Under the statute administered through HHS programs, manufacturers that participate in Medicaid must offer outpatient drugs at or below 340B ceiling prices to eligible covered entities.
Policy fights now center on whether manufacturers may condition discounts on claims-level data submissions for in-house dispenses.
See also Reuters coverage of ongoing 340B overcharge litigation for the broader enforcement climate.
How large is the Bundibugyo Ebola outbreak driving vaccine funding?
According to CDC MMWR modeling for the 2026 Bundibugyo outbreak, 378 confirmed cases and 63 confirmed deaths were recorded as of June 2, 2026.
No approved vaccine or medication currently exists for Orthoebolavirus bundibugyoense, unlike the Zaire strain covered by Ervebo.
CDC warned that weak isolation scenarios could make this among the largest Ebola outbreaks documented.
What is BARDA doing on Bundibugyo vaccines?
HHS preparedness units are seeking vaccine candidates that use the same vesicular stomatitis virus platform as Merck's Ervebo.
Federal partners are also moving investigational therapeutics and diagnostics; see FDA information on Ervebo for the approved Zaire comparator.
Coalition partners have separately announced tens of millions of dollars for Bundibugyo candidate manufacturing and trials.
What remains unresolved for hospitals and vaccine developers?
Whether HRSA will intervene on manufacturer data mandates remains a live policy question for 340B covered entities.
Bundibugyo vaccine programs still need clinical starts; funding alone does not equal Emergency Use Listing or FDA approval.
Hospitals facing June cutoffs must weigh data-sharing burdens against immediate loss of Lilly 340B pricing.
Related NovaPharma coverage
- Eli Lilly 340B data-sharing ultimatum analysis
- Ebola outbreak implications for women and girls
- Lilly vaccine research and biotech buyouts
Frequently Asked Questions
What did Eli Lilly demand from 340B hospitals in June 2026?
Lilly told an initial set of noncompliant covered entities they had five business days to submit claims-level data for in-house and pharmacy dispenses or lose 340B pricing eligibility through wholesalers.
Why does Ebola Bundibugyo vaccine funding matter now?
CDC reported 378 confirmed Bundibugyo cases and 63 deaths as of June 2, 2026, with no approved vaccine for that species, prompting BARDA and partners to fund countermeasure development.
Which agency oversees the 340B Drug Pricing Program?
The Health Resources and Services Administration within HHS administers 340B. Manufacturers must offer outpatient drugs at discounted prices to eligible covered entities that serve safety-net patients.
Primary Sources
Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
